Last month marked the end of an incredible three years of internal medicine residency. Three years full of challenges, joyful times, and long-lasting memories. I am very grateful to my mentors, attendings, resident colleagues, co-workers, and everyone who helped me along the way
- LifeVest (WCD) can be considered in certain high-risk patients <40 days after MI
VEST trial 2018: primary outcome was negative, but ↓ All-cause mortality, limitation --> suboptimal participants adherence
Thank you Dr. Feitell for your guidance and mentorship! @SFeitell
From my Grand Rounds on Post-MI HF ❤️🩹
Key messages:
Post-Myocardial Infarction Heart failure vs chronic Heart Failure 🫀
- There are differences between the post-MI HF population and the chronic HF population. Post-MI HF might derive differential benefits from HF therapies
- Early revascularization (PCI or CABG) was proven to improve ⬆️ survival in acute MI with cardiogenic shock
- Low-dose colchicine showed benefit in post-MI patients (↓24% MACE) in the COLCOT trial (2019)